Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3911643 | 0.89 | KCNA3 (0.44) | KCNA3KMT2ANR2E3KDM4EALDH1A1 | |
| SCHEMBL3909794 | 0.84 | KDM4E (0.56) | KCNA3KMT2AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL5728201 | 0.84 | CYP1A2 (0.51) | KCNA3KMT2ANR2E3KDM4EHSD17B10 | |
| SCHEMBL3918101 | 0.83 | KCNA3 (0.49) | KCNA3CA12CA1CA9ABCG2 | |
| SCHEMBL3911254 | 0.83 | KCNA3 (0.49) | KCNA3ALDH1A1PRKDCCA12CA1 | |
| SCHEMBL3920158 | 0.83 | PIM1 (0.50) | KCNA3KDM4EHSD17B10CA12CA1 | |
| SCHEMBL3909739 | 0.83 | KCNA3 (0.45) | KCNA3KMT2AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL3912517 | 0.81 | KCNA3 (0.72) | KCNA3CA12CA1CA9MAOB | |
| SCHEMBL13842107 | 0.81 | KCNA3 (0.47) | KCNA3KMT2AALDH1A1CA12CA1 | |
| Hydrochloric Acid SCHEMBL3913941 | 0.80 | KCNA3 (0.70) | KCNA3CA12CA1CA9MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667988-B1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMA INC (US) | 2013-04-10 | — | — | EP | claimed |
| EP-1667988-A1 | COUMARINS AS INOS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005026143-A1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050054681-A1 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | claimed |
| EP-1667988-B1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMA INC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-7538233-B2 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538233-B2 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538233-B2 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1667988-A1 | COUMARINS AS INOS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005026143-A1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054681-A1 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054681-A1 | Coumarins as iNOS inhibitors | NOS2, NOS1, NOS3 | KCNA3 3807/4885KMT2A 4703/4885NR2E3 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.